FGFR2 and prostate carcinoma: Down-regulation of FGFR-2 has been also reported in other human neoplasms, including astrocytomas, bladder and prostate carcinomas, pituitary adenomas [20], [25], [26], and FGFR-2 loss-of-function mutations have been identified in melanoma [27].